Manufacturer Supply High Quality CAS 220127-57-1 Imatinib Mesylate

• CAS No.: 220127-57-1
• Formula: C30h35n7o4s
• EINECS: 606-892-3
• Type: Synthesis Material Intermediates
• Appearance: White Powder
• Quality: Industrial
• Model NO.: TY-02AL
• Colour: White
• Package: Foil Bag
• Place: China
• Assay: 99%
• Shelf: 2 Years
• Transport Package: 25kg/Drum 5g, 100g, 500g, 1kg, 10kg, 100kg, 200kg
• Specification: 25kg/drum
• Trademark: tongyon
• Origin: China
• Production Capacity: 5000kg/Month

Product Description

 

Product name	Imatinib mesylate
CAS	220127-57-1
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Imatinib mesylate
Product Name Imatinib mesylate

CAS 220127-57-1

MF C30H35N7O4S

MW 589.71

EINECS 606-892-3

MOL File 220127-57-1.mol

Chemical Properties

Melting point 214-224°C
storage temp.  2-8°C
solubility  H2O: soluble10mg/mL, clear
form  White solid
color  white to beige
InChIKey YLMAHDNUQAMNNX-UHFFFAOYSA-N
CAS DataBase Reference 220127-57-1(CAS DataBase Reference)



Usage And Synthesis
a small-molecule inhibitor

Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.

Description

In May 2001, the FDA approved imatinib as a new cancer drug after a record review time of just 2.5 months. Imatinib was launched as Gleevec in the US for chronic myelogenous leukemia (CML) in blast crisis, accelerated phase or chronic phase after interferon-alpha failure. This compound can be prepared by a four step sequence from a condensation of the 1-(3-pyridyl)ethanone with dimethyl formamide dimethylacetal, followed by successive cyclization with the methyl-nitrophenyl guanidine, hydrogenolysis and condensation with the benzoyl chloridee of the methylpiperazine. Imatinib is the first of a new class of anticancer drugs that are specifically designed to target the molecular pathways involved (oncogenic event) in the development of disease. The Brc-Abl oncoprotein is a constitutively active tyrosine kinase that causes CML. Imatinib is a competitive inhibitor of this tyrosine kinase as well as Abl, Kit and the PDGFR kinases It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates and consequently blocks the proliferation of the leukemic cells. Phase II studies demonstrated that in chronic phase CML, over 90% of the patients had their leukocyte counts return to normal and 56% had a major cytogenic response. No phase III data is currently available. It is clear from the evidence available that imatinib has advantages over IFN-alpha, such as reduced toxicity, more rapid hematological response, higher rate of cytogenic response and oral administration. The drug is well tolerated, producing few side effects, classified as grade 1 nausea, muscle cramps, diarrhea, edema and vomiting. Imatinib is metabolized primarily by the CYP3A4 enzyme system and drugs capable of modulating this system would be expected to modify the patient's exposure. Novartis expects to launch imatinib for the treatment of gastrointestinal stromal tumors in 2002.

GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.